QUVIVIQ Trademark

Trademark Overview

On Tuesday, November 5, 2019, a trademark application was filed for QUVIVIQ with the United States Patent and Trademark Office. The USPTO has given the QUVIVIQ trademark a serial number of 79274313. The federal status of this trademark filing is REGISTERED as of Tuesday, October 6, 2020. This trademark is owned by Idorsia Pharmaceuticals Ltd.. The QUVIVIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for humans for the prevention and treatment of cardiovascular diseases, hypertension, brain haemorrhage and sequelae thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, auto-immune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, diseases and disorders of the central nervous system, dementia, sleep disorders, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases, and cancer
quviviq

General Information

Serial Number79274313
Word MarkQUVIVIQ
Filing DateTuesday, November 5, 2019
Status700 - REGISTERED
Status DateTuesday, October 6, 2020
Registration Number6166353
Registration DateTuesday, October 6, 2020
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 21, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for humans for the prevention and treatment of cardiovascular diseases, hypertension, brain haemorrhage and sequelae thereof, kidney diseases, pulmonary diseases, fibrotic diseases, cystic fibrosis, inflammatory diseases, allergic diseases, auto-immune diseases and disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, diseases and disorders of the central nervous system, dementia, sleep disorders, anxiety disorders, addictions, eating disorders, epilepsy, metabolic disorders, diabetes, glycolipid storage disorders, Fabry disease and symptoms and sequelae of Fabry disease, infectious diseases, and cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 20, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIdorsia Pharmaceuticals Ltd
Party Type31 - New Owner After Registration
Legal Entity Type25 - NOT AVAILABLE
AddressCH
Party NameIdorsia Pharmaceuticals Ltd.
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressCH-4123 Allschwil
CH
Party NameIdorsia Pharmaceuticals Ltd.
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressCH-4123 Allschwil
CH
Party NameIdorsia Pharmaceuticals Ltd.
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH-4123 Allschwil
CH

Trademark Events

Event DateEvent Description
Sunday, February 9, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, December 19, 2019SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, December 20, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 24, 2019APPLICATION FILING RECEIPT MAILED
Saturday, February 8, 2020ASSIGNED TO EXAMINER
Saturday, February 8, 2020NON-FINAL ACTION WRITTEN
Tuesday, March 3, 2020REFUSAL PROCESSED BY MPU
Friday, May 22, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 4, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Saturday, March 21, 2020REFUSAL PROCESSED BY IB
Friday, May 22, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, May 22, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 22, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, May 22, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, May 22, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, May 22, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, May 22, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Saturday, May 23, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 15, 2020ASSIGNED TO LIE
Friday, June 12, 2020EXAMINERS AMENDMENT -WRITTEN
Friday, June 12, 2020EXAMINERS AMENDMENT E-MAILED
Friday, June 12, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, June 12, 2020EXAMINER'S AMENDMENT ENTERED
Friday, June 12, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 1, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, July 15, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, July 15, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, October 6, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, July 21, 2020PUBLISHED FOR OPPOSITION
Tuesday, July 21, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, July 31, 2020NOTIFICATION PROCESSED BY IB
Wednesday, January 6, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, December 11, 2020NEW REPRESENTATIVE AT IB RECEIVED
Friday, August 16, 2024CHANGE OF NAME/ADDRESS REC'D FROM IB
Sunday, February 14, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Saturday, January 23, 2021FINAL DISPOSITION PROCESSED
Saturday, January 23, 2021FINAL DISPOSITION NOTICE SENT TO IB

Related Keywords

quviviq diseases disorders fabry disease sequelae dementia sleep anxiety system nervous